Selected article for: "case test negative control design and control design"
Author: Patalon, T.; Gazit, S.; Pitzer, V. E.; Prunas, O.; Warren, J. L.; Weinberger, D. M.
Title: Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine
  • Cord-id: 7f33cu6l
  • Document date: 2021_8_31
    • ID: 7f33cu6l
    Snippet: With the evidence of waning immunity of the BNT162b2 vaccine, a national third dose vaccination campaign was initiated in Israel during August 2021; other countries have announced their intention to administer a booster shot as well. Leveraging data from Maccabi Healthcare Services, we conducted a preliminary retrospective study aimed at evaluating initial short-term effectiveness of a three dose versus a two dose regimen against infection due to the Delta variant of SARS-CoV-2, using two comple
    Document: With the evidence of waning immunity of the BNT162b2 vaccine, a national third dose vaccination campaign was initiated in Israel during August 2021; other countries have announced their intention to administer a booster shot as well. Leveraging data from Maccabi Healthcare Services, we conducted a preliminary retrospective study aimed at evaluating initial short-term effectiveness of a three dose versus a two dose regimen against infection due to the Delta variant of SARS-CoV-2, using two complementary approaches; a test-negative design and a matched case-control design. We found that 7-13 days after the booster shot there is a 48-68% reduction in the odds of testing positive for SARS-CoV-2 infection and that 14-20 days after the booster the marginal effectiveness increases to 70-84%. Further studies are needed to determine the duration of protection conferred by the third dose and its effect on severe disease.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adequate antibody response: 1, 2, 3, 4
    • acute respiratory syndrome and adjustment matching: 1
    • acute respiratory syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long term effectiveness: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and maccabi healthcare services: 1
    • acute respiratory syndrome coronavirus and additional protection: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome coronavirus and adequate antibody response: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and long term effectiveness: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and maccabi healthcare services: 1
    • additional covariate and logistic regression model: 1
    • adjustment matching and logistic regression model: 1
    • long term effectiveness and maccabi healthcare services: 1